Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that
elevated levels of the hormone prolactin might be associated with an increased risk of breast
cancer. Cabergoline has been shown to lower prolactin levels in the blood.
The purpose of this study is to evaluate the effectiveness of cabergoline in treating
metastatic breast cancer disease in those who test positive for the prolactin receptor.